Biomedical Engineering Reference
In-Depth Information
50. Miri R, Niknahad H, Vesal G, Shafiee A (2002) Synthesis and calcium channel
antagonist activities of 3-nitrooxyalkyl, 5-alkyl1,4-dihydro-2,6-dimethyl-4-(1-methyl-
5-nitro-2-imidazolyl)-3,5-pyridinedicaboxylates. Farmaco 57:123-128
51. Shafiee A, Miri R, Dehpour AR, Solimani F (1996) Syntheses and calcium channel antago-
nist activity of nifedipine containing imidazolyl substitutent. Pharm Sci 2:541-543
52. Miri R, Javidnia K, Kebriaie-Zadeh A, Niknahad H, Shaygani N, Semnanian S, Shafiee A
(2003) Synthesis and evaluation of pharmacological activities of 3,4-dialkyl1,4-dihydro-
2,6-dimethyl- 4-nitroimidazole-3,5-pyridine dicarboxylates. Arch Pharm Pharm Med Chem
336:422-428
53. Miri R, Javidnia K, Mirkhani H, Hemmateenejad B, Sepeher Z, Zalpour M, Behzad T,
Khoshneviszadeh M, Edraki N, Mehdipour AR (2007) Synthesis, QSAR and calcium
channel modulator
activity
of
new hexahydroquinoline
derivatives
containing
nitroimidazole. Chem Biol Drug Des 70:329-336
54. Goldmann S, Stoltefuss J (1991) 1, 4-Dihydropyridines: effects of chirality and conformation
on the calcium antagonist and agonist activities. Angew Chem Int Ed 30:1559-1578
55. Jauk B, Pernat T, Kappe CO (2000) Design and synthesis of a conformationally rigid mimic
of the dihydropyrimidine calcium channel modulator SQ 32,926. Molecules 5:227-239
56. Atwal KS, Rovnyak GC, Schwartz J, Morelan S, Hedberg A, Gougoutas JZ, Malley MF,
Floyd DM (1990) Dihydropyrimidine calcium channel blockers: 2-heterosubstituted
4-aryl-1,4-dihydro-6- methyl-5-pyrimidinecarboxylic acid esters as potent mimics of
dihydropyridines. J Med Chem 33:1510-1515
57. Atwal KS, Rovnyak GC, Kimball SD, Floyd DM, Moreland S, Swanson BN, Gougoutas JZ,
Schwartz J, Smillie KM, Malley MF (1990) Dihydropyrimidine calcium channel blockers. II.
3- Substituted-4-aryl-1, 4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent
mimics of dihydropyridines. J Med Chem 33:2629-2635
58. Atwal KS, Swanson BN, Unger SE, Floyd DM, Moreland S, Hedberg A, O'Reilly BC (1991)
Dihydropyrimidine calcium channel blockers. 3. 3-carbamoyl-4-aryl-1,2,3,4-tetrahydro-
6-methyl- 5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents.
J Med Chem 34:806-811
59. Rovnyak GC, Atwal KS, Hedberg A, Kimball SD, Moreland S, Gougoutas JZ, O'Reilly BC,
Schwartz J, Malley MF (1992) Dihydropyrimidine calcium channel blockers. 4. Basic
3-substituted-4-aryl-1, 4-dihydropyrimidine-5-carboxylic acid esters. Potent antihyperten-
sive agents. J Med Chem 35:3254-3263
60. Gupta SP, Veerman A, Bagar P (2000) Quantitative structure-activity relationship studies on
some series of calcium channel blockers. Mol Divers 8:357-363
61. Harrold M (2002) Angiotensin converting enzyme inhibitors, antagonist and calcium chan-
nel blockers. In: Lemke TL, Williams D (eds) Foye's principles of medicinal chemistry.
Lippincott Williams & Wilkins, Baltimore, MD
62. Mohajeri A, Hemmateenejad B, Mehdipour A, Miri R (2008) Modeling calcium channel
antagonistic activity of dihydropyridine derivatives using QTMS indices analyzed by
GA-PLS and PC-GAPLS. J Mol Graph Model 26:1057-1065
63. Mojarrad JS, Miri R, Knaus EE (2004) Design and synthesis of methyl 2-methyl-7,
7-dihalo-5- phenyl-2-azabicyclo [4.1.0] hept-3-ene-4-carboxylates with calcium channel
antagonist activity. Bioorg Med Chem 12:3215-3220
64. Dagnino L, Li-Kwong-Ken MC, Wolowyk MC, Wynn H, Triggle CR, Knaus EE (1986)
Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-
4-(pyridinyl)-3,5- pyridinedicarboxylates. J Med Chem 29:2524-2529
65. Hemmateenejad B, Miri R, Safarpour MA, Khoshneviszadeh M, Edraki N (2005) Confor-
mational analysis of some new derivatives of 4-nitroimidazolyl-1,4-dihydropyridine-based
calcium channel blockers. J Mol Struct Theochem 717:139-152
66. Mahmoudian M, Richards W (1986) A conformational distinction between dihydropyridine
calcium agonists and antagonists. J Chem Soc Chem Commun 10:739-741
